← All trials
NCT04957719
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 14, 2021
- Primary completion
- Feb 29, 2024
- Completion date
- Feb 29, 2024
- First posted
- Jul 12, 2021
- Last posted
- Nov 19, 2021
- Enrollment
- 14000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Idorsia Pharmaceuticals Ltd.Lead sponsor
- Idorsia Pharmaceuticals Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.